Difluoromescaline
Pharmaceutical compound
From Wikipedia, the free encyclopedia
Difluoromescaline (DFM), also known as 4-difluoromethoxy-3,5-dimethoxyphenethylamine, is a psychedelic drug of the phenethylamine and scaline families related to mescaline.[1][2][3] It is a difluorinated derivative of mescaline.[1][2][3]
- None
| Clinical data | |
|---|---|
| Other names | DFM; 4-Difluoromethoxy-3,5-dimethoxyphenethylamine; 3,5-Dimethoxy-4-difluoromethoxyphenethylamine |
| Routes of administration | Oral[1][2][3] |
| Drug class | Serotonin receptor modulator; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Pharmacokinetic data | |
| Duration of action | 12–18 hours[1][2][3] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C11H15F2NO3 |
| Molar mass | 247.242 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
The drug's dose range is 50 to 100 mg orally and its duration is 12 to 18 hours.[1][2][3] It is about 3- or 4-fold more potent than mescaline and has a longer duration in comparison.[1][2] The drug is said to produce strong psychedelic effects.[3]
Difluoromescaline interacts with serotonin receptors and acts as a low-potency full agonist of the serotonin 5-HT2A receptor.[1][2][3]
It was first described in the scientific literature by Daniel Trachsel in 2012.[2][1][3] The drug's pharmacology was studied in more detail in 2021.[3] It is not a controlled substance in Canada as of 2025.[4]